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ABSTRACT 
Tuberculosis (TB) is an acute infectious disease that primarily 
affects the lungs. Probiotics supplementation can increase the 
number and activity of NK cell in peripheral blood by modulation of 
interleukin-12 (IL-12), thus increasing interfenon-γ (IFN-γ) 
production by T-helper cells type 1 (Th1) response. Vitamin B1 acts 
on macrophages and affects neutrophil motility. Vitamin B6 is 
associated with the release of cytokines and the responsiveness of 
NK cells, while vitamin B12 affects to lymphocytes, Tcell proliferation, 
CD4+ ratios, and NK cell activity. This study aim to analyze the 
effects of probiotics and vitamin B1, B6, B12 supplementation on 
IFN-γ and IL-12 levels during intensive phase of antituberculosis 
treatment. The study was pre-post test randomised control by time 
series. The control group was TB patients with standard therapy of 
antituberculosis and vitamin B6, while the intervention group was TB 
patients receiving therapy plus once daily probiotics and vitamin B1, 
B6, B12 supplementation during the intensive phase. Blood samples 
were withdrawn at baseline, one month, and two months after 
therapy to measure plasma IFN-γ and IL-12 levels using the ELISA 
method. Twenty two patients were divided equally into two groups. 
There was a tendency to greater increase of IFN-γ in the first month 
of the intervention group, followed by a significant decline after 
two-month therapy (p <0.05). In both groups there was a rise in 
IL-12 levels after one month followed by a decrease in the second 
month (p>0.05). However, the percentage was higher in the 
supplementation group. Addition of probiotics and vitamins B1, B6, 
B12 could improve immune response through IL-12 and IFN-γ 
modulation during intensive phase therapy. 
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INTRODUCTION 
Tuberculosis (TB) is an acute infectious 
disease caused by Mycobacterium tuberculosis 
(Mtb). TB can be transmitted from one 
individual to another through airbone droplets. 
Globally, TB is the leading cause of  death from 
a single infectious agent, killing approximately 
1.67 million persons in 2016. At least one 
quarter of  persons worldwide, approximately 
1.7 billion people, are infected with Mtb. 
Among these infected persons, approximately 
10% or 170 million persons globally, will be 
expected to develop TB during their lifetimes 
(WHO, 2018). According to the recent report, 
there are new high burden countries lists for 
the period of 2016–2020 (TB, Multidrug- 
resistant TB (MDR-TB) and TB/ HIV), and 
Indonesia is among the 20 top countries with 
the incident of  10.000 per year for TB, and 
1,000 per year for TB/HIV (WHO, 2017). 
The body's defense system for the 
intracellular bacterial infections which have 
important role are macrophages and Th1 cells. 
Those act as a specific mediator in destroying 
Mtb. Fagocytic cells that influx bacteria and 
become apoptosis will be uptaken by lung 
dendritic cell then transported to lymphe. This 
is the stimulate adaptive immune phase,             
T-helper tipe 1 (Th1) stimulates the cytokine 
secretion (Etna, 2014). Cytokines that have 
important contribution to TB infection include 
IFN-γ, TNF-α, IL-12, IL-17, IL-10, and IL-6. 
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In turn cytokine will stimulate neutrophils and 
activate  macrophages, form   granulomas, and 
form antimicrobial agents such as oxygen and 
nitrogen reactive to inhibit Mtb (Adrian et al, 
2015). 
Probiotics can modulate the immune 
system through the activity of  epithel cells and 
immune cell receptors. In respiratory tract 
infections, there is an increase in the activity of  
fagocytes from alveolar macrophages after the 
administration of  probiotics, thus increasing 
the activity of  NK cells in the IFN-γ 
production (Forsythe, et al., 2013; Mortaz, et al., 
2013).  
Some vitamins can affect to body‟s 
immunity, including cell-mediated immunity, 
humoral immunity, and phagocytic activity of  
leucocytes. Vitamin B1 has an action in 
macrophages and affects neutrophil motility. 
Vitamin B6 can release cytokines or chemokines 
and has responsibility to the responsiveness of  
NK cells. In addition, vitamin B12 increases 
lymphocytes as well as improves the abnormal 
CD4/CD8 ratio and NK cell activity (Shetty et 
al, 2010; Spinas et al, 2015). 
The use of  probiotics and vitamin B1, B6, 
B12 supplementation in tuberculosis patient has 
not yet been determined. Therefore, this study 
was aimed to analyze the effects of  those 
supplementation on IFN-γ and IL-12 levels in 
tuberculosis patients. 
 
MATERIALS AND METHODS 
The study protocol was ethically 
approved by the Ethics and Law Committee of  
Airlangga University Hospital on August 2016. 
The study was pre-post test randomised control 
by time series applied to the naïve and 
newly-diagnosed TB patients. The first group 
consisted of  patients with the first-line standard 
therapy of  oral antituberculosis and vitamin B6 
(control), whereas the second group was 
patients receiving therapy and supplementation 
of  probiotics and vitamin B1, B6, B12 
(intervention). Both standard therapy and 
supplementation were administered once daily 
during the intensive phase of  treatment. The 
study was conducted at the Universitas 
Airlangga Hospital and Primary Healthcare 
Centers in Surabaya within period of  
December  2016  and  February  2017. The  
 
inclusion criteria were patients aged 18-65 years,  
diagnosed with active TB, started first-line 
antituberculosis treatment for the intensive 
phase, had no previous history of  probiotics and 
vitamin B1, B6, B12 before enrollment, and 
signed the informed consent. The exclusion 
criteria were patients with HIV co-infection, 
pregnancy, lactation, diabetes mellitus, 
pneumonia, and current administration of  
corticosteroids or other immunosuppressants.   
Multistrain probiotics (Lactobaccilus 
acidophilu, L. casei, L. rhamnosus, L. bulgaricus, 
Bifidobacterium breve, B. longum, Streptococcus 
thermophilus), vitamin B1 100mg, B6 100mg, B12 
5.000mcg were administered once daily in the 
intervention (second) group. Blood samples 
were withdrawn at baseline, after one month, 
and two months of  intensive therapy for further 
plasma IFN-γ and IL-12 assay using the ELISA 
method. The t-test analysis was performed to 
evaluate the effects of  probiotics and vitamin B 
supplementation.  
 
RESULTS AND DISCUSSION 
The characteristics of  patients (Table I) 
Data were distributed normally, and no 
significant differences were found between the 
two groups (p>0.05). 
The Figure 1A and 2 A showed the 
plasma IFN-γ levels in both groups. The levels 
increased from 32.735pg/mL before therapy to 
40.325pg/mL (p=0.445) after one month 
followed by a decrease to 39.640pg/mL 
(p=0.859) in the second month. Whereas, 
plasma IFN-γ levels in the intervention group 
rose from 73.767pg/mL before therapy to 
97.768pg/mL (p=0.241) in the first month and 
next significantly declined to 43.472pg/mL 
(p=0.007) at the end of  two-month of  intensive 
therapy. 
Similarly, figures 1B and 2B revealed that 
plasma IL-12 levels in the control group 
elevated from 2.663pg/mL before therapy to 
3.303pg/mL (p=0.091) in the first month and 
diminished to 2.550pg/mL (p = 0.155) after 
two months of  therapy. In addition, plasma 
IL-12 levels of  the intervention group 
increased from 3.173pg/mL before therapy to 
4.168pg/mL (p=0.061) after one and decreased 
significantly to 2.567pg/mL (p=0.003) in the 
second month. 
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This study recruited 22 newly-diagnosed 
TB patients and were divided equally into each 
group. The diagnosis was primarily based on the 
Acid-Fast Bacilli (AFB) smear results or chest 
x-ray, in addition to clinical features such as 
cough and night sweats. Although most patients 
experienced pulmonary TB rather than 
extrapulmonary type, the process of body 
immune system response to Mtb for both 
conditions is similar (Adrian et al, 2015). All 
patients were administered the first-line 
antituberculosis therapy as standard therapy 
according to the current WHO guideline 
(WHO, 2017). 
Probiotics are microorganisms alive that 
given in sufficient quantities to provide benefits. 
They have shown to increase the amount and 
activity of  cytotoxic NK cells in peripheral 
blood, with IL-12 immunomodulation 
increasing the expression of  NK cell receptors. 
Thus, it can be concluded that probiotics are 
capable of  increasing Th1 responses (Kechagia, 
et al, 2013; Nanno, et al, 2014). For example, the 
L. pentosus strain significantly increased the 
activity of  NK cells in the spleen through 
IL-12. Increased levels of  IL-12 in dendritic 
cells cause NK stimulation, thus increasing 
IFN-production (Forsythe, 2013; Mortaz, et al, 
2013). Previous studies have shown that 
combination of  multistrain probiotics provide 
better results because they produce synergistic 
effects among strains to inhibit more 
pathogens. Another study also revealed that the 
use of  probiotics is useful in reducing the 
incidence of  respiratory tract infections 
(Chapman et al, 2011; Chapman et al, 2012). 
Table I. Patients demography 
 
Parameter Control group N (%) Intervention group N (%) p value* 
Total 11 11  
Gender 
Male 4 (36.4) 4 (36.4) 
1.000 
Female 7 (63.6) 7 (63.6) 
Age (years) 
18-24 2 (18.2) 2 (18.2) 
0.389 
25-34 2 (18.2) 2 (18.2) 
35-44 2 (18.2) 5 (45.4) 
45-54 4 (36.3) 1 (9.1) 
55-65 1 (9.1) 1 (9.1) 
AFB smear result 
Positive 7 (63.6) 6 (54.5) 
1.000 
Negative 4 (36.4) 5 (45.5) 
Duration of symptoms (cough, night sweats) 
≥ 1 month 9 (81.8) 11 (100.0) 
0.065 
< 1 month 2 (18.2) 0 (0) 
Smoking 
Yes 1 (9.1) 1 (9.1) 
1.000 
No 10 (90.9) 10 (90.9) 
Co-morbidities 
Asthma 0 (0) 1 (9.1) 
0.413 
Hyperthyroid 0 (0) 1 (9.1) 
Ulcer 1 (9.1) 2 (18.2) 
None 10 (90.9) 7 (63.6) 
Diagnosed TB 
Pulmonary 7 (63.6) 10 (90.9) 
0.311 
Extrapulmonary   4 (36.4)   1 (9.1) 
 
* calculated by chi-square test for categorical variables  
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Figure 1. Changes in plasma IFN-γ (A) and IL-12 (B) levels in the control and intervention groups 
before therapy (t0), after one month (t1), and two months of  intensive phase therapy (t2).  
 
  
 
 
 
Figure 2. Differences within a month between IFN- γ and IL-12 levels in in the control and 
intervention groups during the intensive phase therapy 
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Vitamins also affect the body's immunity, 
such as vitamin B1 which works on 
macrophages and influences the neutrophil 
motility, vitamin B6 is associated with the 
release of  cytokines or chemokine‟s and 
responsiveness of  NK cells, and vitamin B12 
influences lymphocytes, T cell proliferation, 
CD4/CD8 and NK cells activity (Shetty et al, 
2010; Spinas et al, 2015). 
Furthermore, combination of  multistrain 
probiotics and vitamin B supplementation 
provides enhanced immunomodulation 
activities during the intensive phase therapy as 
shown by the trends of  increase in the first 
month and decrease at the end of  intensive 
therapy between IFN-γ and IL-12 levels in the 
intervention group compared to the control 
group. Clifford et al (2015) reported that there 
was an increase in IFN-γ levels in active TB 
treatment. When the host is infected by Mtb, 
there will be bacterial influx by phagocytic cells, 
especially alveolar macrophages and neutrophil, 
which in turn induce apoptosis. The apototic 
cells will be captured by pulmonary dendritic 
cells that act as antigens presenting cell (APC) 
to be carried into lymph with the help of  IL-12 
and chemokines. Dendritic cells also produce 
IL-12 to support differentiation of  naive T cells 
into helper T cells (Th1, Th2, TTh9, Th 17, Th 
22 and T regulator cells). In the lung, T cells 
produce various cytokines such as TNF-α            
and IFN-γ by Th1 cells (O‟Garra et al, 2013).  
In early infection phase and first month              
of  antituberculosis therapy, probiotics and 
vitamin B supplementation will enhance IFN-γ 
production, but further the IFN-γ level will 
gradually decrease along with the decrease of  
inflammation process at the end of  intensive 
treatment (Abul et al, 2016). 
Indeed, the levels of  IFN-γ were higher 
in the first month of  the intervention group 
compared to the control. This suggested that 
the supplementation of  probiotics and vitamin 
B1, B6, B12 plays a role in the modulation of  
IFN-γ secretion in response to Mtb infection. 
Increased IFN-γ levels in the first month may 
enhance bacteria eradication, as the result the 
bacteria in the lung or extrapulmonary sites will 
decrease resulting reduced systemic 
inflammation. Therefore, at the end of  
intensive therapy the levels of  IFN-γ were 
diminished as shown by a significant reduction 
in the intervention group. Nevertheless, Devici 
et al (2005) stated that there was a significant 
increase in IFN-γ levels in the second month 
and then decreased in subsequent months.  
Interestingly, the similar trends also 
applied to the IL-12 levels. They increased in 
the first month and then decreased in the 
second month of  therapy either in control or 
intervention groups. However, the net 
differences showed greater in the intervention 
group rather than in the control. IL-12 
supports Th1 cell defferention whose secretes 
IFN-γ, and then IFN-γ will stimulate NK cell 
to produce more IFN-γ (Forsythe, 2011). Sai 
Priya et al (2009) revealed a decrease in IL-12 
response during treatment. This suggested that 
supplementation may help increase levels of  
IL-12 in the first month, regulate the balance 
of  T-cell responses and stimulate NK cells in 
the spleen through IL-12 and increase 
production IFN-γ (Spinas et al, 2015). IFN-γ 
will in turn help to eradicate the bacteria. 
Reduced levels of  IL-12 were aligned with the 
levels of  IFN-γ. At the end of  intensive 
therapy, the number of  active Mtb has 
decreased, thus reducing the levels of  IFN-γ 
and IL-12 levels. 
Last, this study was conducted in limited 
number of  patients, so the results cannot be 
directly generalized to greater population. 
Therefore, multi-center study with more subject 
is needed.  
 
CONCLUSIONS 
Supplementation of  once-daily 
multistrain probiotics and vitamin B1, B6 and 
B12 could improve immune system through 
IFN-γ and IL-12 modulation, increase plasma 
levels of  IFN-γ and IL-12 in early phase to help 
speed up Mtb eradication during the intensive 
phase of  tuberculosis treatment.  
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